For Generics, A Victory Lap – And A Warning – On Drug Shortages

 
• By Nielsen Hobbs

Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

AAM’S JONATHAN KIMBALL, LUPIN’S ALOK SONIG, MAYNE PHARMA’S HEM PANDYA, AND WASHINGTON UNIVERSITY’S ANTHONY SARDELLA DISCUSS WHAT WENT RIGHT WITH THE GENERIC INDUSTRY’S COVID RESPONSE.
AAM’S JONATHAN KIMBALL, LUPIN’S ALOK SONIG, MAYNE PHARMA’S HEM PANDYA, AND WASHINGTON UNIVERSITY’S ANTHONY SARDELLA DISCUSS WHAT WENT RIGHT WITH THE GENERIC INDUSTRY’S COVID RESPONSE. • Source: Nielsen Hobbs

More from Generics

More from Products